Synopsis
Synopsis
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector


1. 5 Formyltetrahydrofolate
2. 5 Formyltetrahydropteroylglutamate
3. 5-formyltetrahydrofolate
4. 5-formyltetrahydropteroylglutamate
5. Acid, Folinic
6. Calcium Folinate
7. Citrovorum Factor
8. Factor, Citrovorum
9. Folinate, Calcium
10. Folinic Acid
11. Folinic Acid Sf
12. Folinic Acid-sf
13. Leucovorin
14. Leucovorin, (d)-isomer
15. Leucovorin, (dl)-isomer
16. Leucovorin, (r)-isomer
17. Leucovorin, Calcium
18. Leucovorin, Calcium (1:1) Salt
19. Leucovorin, Calcium (1:1) Salt, (dl)-isomer
20. Leucovorin, Calcium (1:1) Salt, Pentahydrate
21. Leucovorin, Monosodium Salt
22. Leukovorin
23. Leukovorum
24. Monosodium Salt Leucovorin
25. N(5)-formyltetrahydrofolate
26. Wellcovorin
1. Calcium Folinate
2. Calcium Citrovorum Factor
3. Folinic Acid Calcium Salt
4. Folinic Acid-sf, Calcium Salt
5. (+)-l-folinic Acid, Calcium Salt
6. 1492-18-8
7. Nsc3590
8. Sr-05000001662
9. Pharmakon1600-01500364
10. Nsc757083
11. Nsc-757083
12. Sr-05000001662-1
13. Sr-05000001662-2
14. Glutamic Acid,6,7,8-tetrahydro-4-hydroxy-6- Pteridinyl)methyl]amino]benzoyl]-, Calcium Salt (1:1), L-
15. L-glutamic Acid,4,5,6,7,8-hexahydro-4-oxo-6- Pteridinyl)methyl]amino]benzoyl]-, Calcium Salt (1:1), (s)-
| Molecular Weight | 513.5 g/mol |
|---|---|
| Molecular Formula | C20H23CaN7O7+2 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 9 |
| Exact Mass | 513.1284869 g/mol |
| Monoisotopic Mass | 513.1284869 g/mol |
| Topological Polar Surface Area | 216 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 2 |
| Complexity | 911 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Antidotes
Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)
Vitamin B Complex
A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AF - Detoxifying agents for antineoplastic treatment
V03AF03 - Calcium folinate
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Calcium Folinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Calcium Folinate manufacturer or Calcium Folinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Calcium Folinate manufacturer or Calcium Folinate supplier.
A 1492-18-8 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 1492-18-8, including repackagers and relabelers. The FDA regulates 1492-18-8 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 1492-18-8 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 1492-18-8 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A 1492-18-8 supplier is an individual or a company that provides 1492-18-8 active pharmaceutical ingredient (API) or 1492-18-8 finished formulations upon request. The 1492-18-8 suppliers may include 1492-18-8 API manufacturers, exporters, distributors and traders.
click here to find a list of 1492-18-8 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A 1492-18-8 DMF (Drug Master File) is a document detailing the whole manufacturing process of 1492-18-8 active pharmaceutical ingredient (API) in detail. Different forms of 1492-18-8 DMFs exist exist since differing nations have different regulations, such as 1492-18-8 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 1492-18-8 DMF submitted to regulatory agencies in the US is known as a USDMF. 1492-18-8 USDMF includes data on 1492-18-8's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 1492-18-8 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 1492-18-8 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 1492-18-8 Drug Master File in Japan (1492-18-8 JDMF) empowers 1492-18-8 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 1492-18-8 JDMF during the approval evaluation for pharmaceutical products. At the time of 1492-18-8 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 1492-18-8 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 1492-18-8 Drug Master File in Korea (1492-18-8 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 1492-18-8. The MFDS reviews the 1492-18-8 KDMF as part of the drug registration process and uses the information provided in the 1492-18-8 KDMF to evaluate the safety and efficacy of the drug.
After submitting a 1492-18-8 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 1492-18-8 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 1492-18-8 suppliers with KDMF on PharmaCompass.
A 1492-18-8 CEP of the European Pharmacopoeia monograph is often referred to as a 1492-18-8 Certificate of Suitability (COS). The purpose of a 1492-18-8 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 1492-18-8 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 1492-18-8 to their clients by showing that a 1492-18-8 CEP has been issued for it. The manufacturer submits a 1492-18-8 CEP (COS) as part of the market authorization procedure, and it takes on the role of a 1492-18-8 CEP holder for the record. Additionally, the data presented in the 1492-18-8 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 1492-18-8 DMF.
A 1492-18-8 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 1492-18-8 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of 1492-18-8 suppliers with CEP (COS) on PharmaCompass.
A 1492-18-8 written confirmation (1492-18-8 WC) is an official document issued by a regulatory agency to a 1492-18-8 manufacturer, verifying that the manufacturing facility of a 1492-18-8 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 1492-18-8 APIs or 1492-18-8 finished pharmaceutical products to another nation, regulatory agencies frequently require a 1492-18-8 WC (written confirmation) as part of the regulatory process.
click here to find a list of 1492-18-8 suppliers with Written Confirmation (WC) on PharmaCompass.
1492-18-8 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 1492-18-8 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right 1492-18-8 GMP manufacturer or 1492-18-8 GMP API supplier for your needs.
A 1492-18-8 CoA (Certificate of Analysis) is a formal document that attests to 1492-18-8's compliance with 1492-18-8 specifications and serves as a tool for batch-level quality control.
1492-18-8 CoA mostly includes findings from lab analyses of a specific batch. For each 1492-18-8 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
1492-18-8 may be tested according to a variety of international standards, such as European Pharmacopoeia (1492-18-8 EP), 1492-18-8 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (1492-18-8 USP).